Further studies are needed to ascertain whether CAD, CPS1, and the combined CAD–CPS1 score are of predictive value, and whether new therapeutic agents inhibiting pyrimidine synthesis may also be a treatment option in HCC patients. This evidence concerns the gene CAD and hepatocellular carcinoma.